论文部分内容阅读
目的:观察消癌平注射液联合DCT自体免疫细胞治疗原发性肝癌的临床疗效。方法:将60例原发性肝癌患者分为治疗组和对照组各30例,治疗组应用消癌平注射液加DCT自体免疫细胞治疗。对照组单纯接受最佳支持治疗,比较两组患者的临床疗效。结果:治疗组患者瘤体较对照组稳定,近期疗效明显,CD3+,CD4+,CD4+/CD8+较对照组明显增高(P<0.05),生活质量高于对照组(P<0.05)。治疗前、后两组患者肝肾功能比较差异无统计学意义。没有患者因治疗导致肝肾功能损害。结论:消癌平联合DCT自体免疫细胞可有效提高中晚期肝癌患者的免疫力,改善患者的生存质量,是治疗中晚期肝癌患者的一种较好方法。
Objective: To observe the clinical effect of Xiao-Jin-Ping injection combined with DCT auto-immune cells in the treatment of primary liver cancer. Methods: 60 patients with primary liver cancer were divided into treatment group and control group, 30 cases each. The treatment group was treated with Xiaojianping injection plus DCT autoimmune cell therapy. The control group received the best supportive treatment only and compared the clinical efficacy of the two groups. Results: The tumor volume of the treated group was more stable than that of the control group, and the curative effect was obvious in the short term. The levels of CD3 +, CD4 +, CD4 + / CD8 + were significantly increased (P <0.05) and the quality of life was higher than that of the control group (P <0.05). There was no significant difference in liver and kidney function between the two groups before and after treatment. No patient due to treatment lead to liver and kidney dysfunction. Conclusion: Xiaoreping combined with DCT autoimmune cells can effectively improve the immunity of patients with advanced liver cancer and improve the quality of life of patients, which is a good way to treat patients with advanced liver cancer.